Supernus Pharmaceuticals Inc

S49

Company Profile

  • Business description

    Supernus Pharmaceuticals Inc is a specialty pharmaceutical company. The company is engaged in developing and commercializing products for the treatment of central nervous system diseases, including neurological and psychiatric disorders. Its diverse neuroscience portfolio includes approved treatments for epilepsy, migraine, attention-deficit hyperactivity disorder (ADHD), hypomobility in Parkinson's Disease (PD), cervical dystonia, chronic sialorrhea, dyskinesia in PD patients receiving levodopa-based therapy, and drug-induced extrapyramidal reactions in adult patients. The company's products include Trokendi XR, Oxtellar XR, Qelbree, APOKYN, XADAGO, MYOBLOC, GOCOVRI, Osmolex ER, and others.

  • Contact

    9715 Key West Avenue
    RockvilleMD20850
    USA

    T: +1 301 838-2500

    E: [email protected]

    https://www.supernus.com

  • Sector

    Healthcare

    Stock type

    Defensive

  • Industry

    Drug Manufacturers - Specialty & Generic

    Fiscal Year End

    31 December 2026

    Employees

    778

Stocks News & Analysis

stocks

Lower production and higher prices for ASX hydrocarbon play

Improving pricing offsets severe weather impact on sales volumes.
stocks

Alphabet returns on AI investments accelerating

AI propels business across aegments, cloud is grightest; Increasing our fair value.
stocks

We lift our fair value estimate for this ASX energy play

Strong oil and LNG prices are a major win, though we don’t think they will stay high in the long term.

Morningstar Investment Ideas

Markets

Index
Last price
Change
% Change
All Ordinaries8,890.6020.100.23%
CAC 408,072.1331.96-0.39%
DAX 4023,954.5663.70-0.27%
Dow JONES (US)48,861.81280.12-0.57%
FTSE 10010,213.11119.68-1.16%
HKSE25,966.21145.63-0.56%
NASDAQ24,673.249.440.04%
Nikkei 22559,246.03671.43-1.12%
NZX 50 Index12,809.3839.080.31%
S&P 5007,135.952.85-0.04%
S&P/ASX 2008,664.7024.500.28%
SSE Composite Index4,116.448.930.22%

Market Movers